Bioanalytical method for evaluating the pharmacokinetics of the GCP-II inhibitor 2-phosphonomethyl pentanedioic acid (2-PMPA)

Journal of Pharmaceutical and Biomedical Analysis

Volumn 88, Issue , 2014, Pages 162-169

  Rais, Rana ^a   Rojas, Camilo ^a   Wozniak, Krystyna ^a   Wu, Ying ^a   Zhao, Ming ^b   Tsukamoto, Takashi ^a   Rudek, Michelle A ^b   Slusher, Barbara S ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

2 PMPA; Brain plasma ratio; Derivatization; Glutamate carboxypeptidase II; Pharmacokinetics

Indexed keywords

2 PHOSPHONOMETHYL PENTANEDIOIC ACID; ACETONITRILE; GLUTAMATE CARBOXYPEPTIDASE II INHIBITOR; GLUTARIC ACID DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CHEMICAL STRUCTURE; DERIVATIZATION; DRUG CLEARANCE; DRUG DISTRIBUTION; ELECTROSPRAY; MALE; NONHUMAN; PRECIPITATION; PRIORITY JOURNAL; RAT; SCIATIC NERVE; SPINAL GANGLION; TANDEM MASS SPECTROMETRY;

2-PHOSPHONOMETHYL PENTANEDIOIC ACID; 2-PHOSPHONOMETHYL SUCCINIC ACID; 2-PMPA; 2-PMSA; ABOVE UPPER LIMITS OF QUANTITATION; ANOVA; AREA UNDER THE CONCENTRATION-TIME CURVE; AUC; AULQ; BRAIN/PLASMA RATIO; C(MAX); CE; COLLISION CELL EXIT POTENTIAL; COLLISION ENERGY; CXP; DECLUSTERING POTENTIAL; DERIVATIZATION; DORSAL ROOT GANGLION; DP; DRG; ENTRANCE POTENTIAL; EP; GCP-II; GLUTAMATE CARBOXYPEPTIDASE-II; HIGH QUALITY CONTROL; HQC; LLOQ; LOW QUALITY CONTROL; LOWER LIMIT OF QUANTITATION; LQC; MAXIMUM PLASMA CONCENTRATION; MEDIUM QUALITY CONTROL; MQC; MTBSTFA; N-ACETYL-ASPARTYL GLUTAMATE; N-ACETYLATED-ALPHA-LINKED ACIDIC DIPEPTIDASE; N-TERT-BUTYLDIMETHYSILYL-N-METHYL TRIFLUOROACETAMIDE; NAAG; NAALADASE; ONE-WAY ANALYSIS OF VARIANCE; PHARMACOKINETICS; PROSTATE SPECIFIC MEMBRANE ANTIGEN; PSMA; T(MAX); TIME TO C(MAX);

ANIMALS; AREA UNDER CURVE; BRAIN; CALIBRATION; CHEMISTRY TECHNIQUES, ANALYTICAL; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, LIQUID; ENZYME INHIBITORS; GANGLIA, SPINAL; GLUTAMATE CARBOXYPEPTIDASE II; INFUSIONS, PARENTERAL; MALE; ORGANOPHOSPHORUS COMPOUNDS; PLASMA; RATS; RATS, WISTAR; SCIATIC NERVE; TANDEM MASS SPECTROMETRY; TISSUE DISTRIBUTION;

EID: 84884220816     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2013.08.028     Document Type: Article

References (25)

1. Barinka C., Rojas C., Slusher B., Pomper M. Glutamate carboxypeptidase II in diagnosis and treatment of neurologic disorders and prostate cancer. Curr. Med. Chem. 2013, 19:856-870.
2. Neale J.H., Olszewski R.T., Gehl L.M., Wroblewska B., Bzdega T. The neurotransmitter N-acetylaspartylglutamate in models of pain, ALS, diabetic neuropathy, CNS injury and schizophrenia. Trends Pharmacol. Sci. 2005, 26:477-484.
3. Rahn K.A., Slusher B.S., Kaplin A.I. Glutamate in CNS neurodegeneration and cognition and its regulation by GCPII inhibition. Curr. Med. Chem. 2013, 19:1335-1345.
4. Slusher B.S., Vornov J.J., Thomas A.G., Hurn P.D., Harukuni I., Bhardwaj A., Traystman R.J., Robinson M.B., Britton P., Lu X.C., Tortella F.C., Wozniak K.M., Yudkoff M., Potter B.M., Jackson P.F. Selective inhibition of NAALADase, which converts NAAG to glutamate, reduces ischemic brain injury. Nat. Med. 1999, 5:1396-1402.
5. Jackson P.F., Cole D.C., Slusher B.S., Stetz S.L., Ross L.E., Donzanti B.A., Trainor D.A. Design, synthesis, and biological activity of a potent inhibitor of the neuropeptidase N-acetylated alpha-linked acidic dipeptidase. J. Med. Chem. 1996, 39:619-622.
6. Tortella F.C., Lin Y., Ved H., Slusher B.S., Dave J.R. Neuroprotection produced by the NAALADase inhibitor 2-PMPA in rat cerebellar neurons. Eur. J. Pharmacol. 2000, 402:31-37.
7. Chen S.R., Wozniak K.M., Slusher B.S., Pan H.L. Effect of 2-(phosphono-methyl)-pentanedioic acid on allodynia and afferent ectopic discharges in a rat model of neuropathic pain. J. Pharmacol. Exp. Ther. 2002, 300:662-667.
8. Wozniak K.M., Rojas C., Wu Y., Slusher B.S. The role of glutamate signaling in pain processes and its regulation by GCP II inhibition. Curr. Med. Chem. 2012, 19:1323-1334.
9. Yamamoto T., Nozaki-Taguchi N., Sakashita Y., Spinal N-acetyl-alpha-linked acidic dipeptidase (NAALADase) inhibition attenuates mechanical allodynia induced by paw carrageenan injection in the rat. Brain Res. 2001, 909:138-144.
10. Yamamoto T., Nozaki-Taguchi N., Sakashita Y., Inagaki T. Inhibition of spinal N-acetylated-alpha-linked acidic dipeptidase produces an antinociceptive effect in the rat formalin test. Neuroscience 2001, 102:473-479.
11. Witkin J.M., Gasior M., Schad C., Zapata A., Shippenberg T., Hartman T., Slusher B.S. NAALADase (GCP II) inhibition prevents cocaine-kindled seizures. Neuropharmacology 2002, 43:348-356.
12. Luszczki J.J., Mohamed M., Czuczwar S.J. 2-Phosphonomethyl-pentanedioic acid (glutamate carboxypeptidase II inhibitor) increases threshold for electroconvulsions and enhances the antiseizure action of valproate against maximal electroshock-induced seizures in mice. Eur. J. Pharmacol. 2006, 531:66-73.
13. Popik P., Kozela E., Wrobel M., Wozniak K.M., Slusher B.S. Morphine tolerance and reward but not expression of morphine dependence are inhibited by the selective glutamate carboxypeptidase II (GCP II, NAALADase) inhibitor, 2-PMPA. Neuropsychopharmacology 2003, 28:457-467.
14. Shippenberg T.S., Rea W., Slusher B.S. Modulation of behavioral sensitization to cocaine by NAALADase inhibition. Synapse 2000, 38:161-166.
15. Ghadge G.D., Slusher B.S., Bodner A., Canto M.D., Wozniak K., Thomas A.G., Rojas C., Tsukamoto T., Majer P., Miller R.J., Monti A.L., Roos R.P. Glutamate carboxypeptidase II inhibition protects motor neurons from death in familial amyotrophic lateral sclerosis models. Proc. Natl. Acad. Sci. USA 2003, 100:9554-9559.
16. Rahn K.A., Watkins C.C., Alt J., Rais R., Stathis M., Grishkan I., Crainiceau C.M., Pomper M.G., Rojas C., Pletnikov M.V., Calabresi P.A., Brandt J., Barker P.B., Slusher B.S., Kaplin A.I. Inhibition of Glutamate Carboxypeptidase II (GCPII) activity as a treatment for cognitive impairment in multiple sclerosis. Proc. Natl. Acad. Sci. USA 2012, 109:20101-20106.
17. Nagel J., Belozertseva I., Greco S., Kashkin V., Malyshkin A., Jirgensons A., Shekunova E., Eilbacher B., Bespalov A., Danysz W. Effects of NAAG peptidase inhibitor 2-PMPA in model chronic pain - relation to brain concentration. Neuropharmacology 2006, 51:1163-1171.
18. Richardson D.D., Caruso J.A. Derivatization of organophosphorus nerve agent degradation products for gas chromatography with ICPMS and TOF-MS detection. Anal. Bioanal. Chem. 2007, 388:809-823.
19. Guidance for Industry: Bioanalytical Method Validation 2001, US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER) and Center for Veterinary Medicine (CVM), http://www.fda.gov/cder/guidance/index.htm.
20. Richardson D.D., Caruso J.A. Screening organophosphorus nerve agent degradation products in pesticide mixtures by GC-ICPMS. Anal. Bioanal. Chem. 2007, 389:679-682.
21. Rosing H., Man W.Y., Doyle E., Bult A., Beijnen J.H. Bioanalytical liquid chromatographic method validation. A review of current practices and procedures. J. Liquid Chromatogr. Rel. Technol. 2000, 23:329-354.
22. Paglia G., D'Apolito O., Garofalo D., Scarano C., Corso G. Development and validation of a LC/MS/MS method for simultaneous quantification of oxcarbazepine and its main metabolites in human serum. J. Chromatogr. B, Anal. Technol. Biomed. Life Sci. 2007, 860:153-159.
23. Perrier D., Gibaldi M. Noncompartmental Analysis Based on Statistical Moment Theory, Pharmacokinetics 1982, 409-417. Marcel Dekker, New York, NY. 2nd ed.
24. Barinka C., Rojas C., Slusher B., Pomper M. Glutamate carboxypeptidase II in diagnosis and treatment of neurologic disorders and prostate cancer. Curr. Med. Chem. 2012, 19:856-870.
25. Carozzi V.A., Chiorazzi A., Canta A., Lapidus R.G., Slusher B.S., Wozniak K.M., Cavaletti G. Glutamate carboxypeptidase inhibition reduces the severity of chemotherapy-induced peripheral neurotoxicity in rat. Neurotox. Res. 2010, 17:380-391.